Insitro is a data-driven drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. insitro's approach focuses on the development of predictive machine learning models to be brought to bear on key bottlenecks in pharmaceutical R&D. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/15/21	$400,000,000	Series C	Alexandria Venture Investments ARCH Venture Partners Canada Pension Plan Investment Board Casdin Capital Foresite Capital GV HOF Capital T. Rowe Price Associates Third Rock Ventures Two Sigma Ventures	undisclosed